[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-sutro-biopharma-nasdaqstro-rec33019ae745-94d4-7abf-8e0c-a187f8f8fa4a":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":11,"showTags":12,"source":13,"reactions":14,"selfReactions":15,"logo":16,"sourceId":17,"sourceUserId":18,"asset":19,"tagsCategories":20,"totalComments":21,"lang":22,"unique_views_count":21},"sutro-biopharma-nasdaqstro-rec33019ae745-94d4-7abf-8e0c-a187f8f8fa4a","1764815689000","Sutro Biopharma (NASDAQ:STRO) Receives \"Neutral\" Rating from Wedbush","Wedbush  reiterated a \"neutral\" rating and set a $10.00 price objective (up previously from $2.00) on shares of Sutro Biopharma in a research report on Tuesday.","https://www.marketbeat.com/instant-alerts/sutro-biopharma-nasdaqstro-receives-neutral-rating-from-wedbush-2025-12-02/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","[\"\"]","[{\"name\":\"\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/blockchains/.png\"}]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Other\"]","0","EN"]